Raise Capital
Products
Resources
April 14, 2025
Let's face it – if you're building a robotics startup in 2025, you're caught in a strange paradox. On one hand, investor interest in AI-powered robotics investment is surging, leading to record-breaking mega-rounds for a few lucky startups. On the other hand, many robotics ventures – especially those in growth stages – grapple with long R&D cycles, hardware-software integration costs, and cautious institutional investors.
As a robotics founder or executive, how can you navigate capital raising in 2025 effectively? This article breaks down the latest strategies for robotics venture funding, exploring both traditional and alternative funding paths that can help you succeed.
Here's the reality: robotics funding is booming, but it's not evenly distributed. In 2024, robotics startups raised around $6.4 billion by Q4, tracking toward $7.5 billion for the year, far exceeding 2023's $6.9 billion. While that figure is shy of the 2021 peak ($14.7B), it signals that plenty of investors continue to bet on robotics.
The challenge? This funding is becoming increasingly concentrated. In 2024 there were only about 473 funding rounds, down from 671 the year before. This means bigger checks are going to fewer companies.
You've probably seen the headlines – Figure raising $675 million, Physical Intelligence securing $400 million at a $2B valuation, or Apptronik landing $350 million in a Series A with backing from Google. These mega-rounds create the impression that robotics funding is easy to come by. But for most growth-stage companies, the reality is different.
Two words: Artificial Intelligence.
Investors are particularly enthusiastic about AI-powered robotics startups that promise versatile capabilities. Instead of funding robots built for one narrow task, VCs are chasing companies developing flexible, multi-purpose robots with advanced "brains." Many of these big funding winners share notable backers like Amazon's Jeff Bezos, who has been investing heavily in next-generation robotics platforms.
If your technology leverages AI to make robots smarter or more versatile, you've got a narrative that resonates with today's investors. This AI-powered robotics investment boom is creating opportunities for startups that can demonstrate intelligence and adaptability in their solutions.
While warehouse automation dominated the last funding cycle, healthcare robotics is emerging as the next frontier. According to Intuitive Ventures, healthcare is poised to be the next big robotics success story after warehouse/fulfillment.
Investors are increasingly drawn to robots that can perform or assist in medical procedures – from hospital service robots to orthopedic surgical systems. This interest has been validated by major exits like J&J's $3.4B acquisition of Auris Health and Stryker's $1.65B acquisition of Mako Surgical.
As Oliver Keown of Intuitive Ventures puts it, there are "untapped clinical domains" where robotics can deliver real impact. If you're working in healthcare robotics, orthopedic robotics, or robotic-assisted surgery, you're in one of 2025's most investor-friendly niches.
Despite the strong overall numbers, robotics founders face unique hurdles:
Building robots isn't like developing an app. You're creating physical machines AND the software to run them. This dual challenge means higher upfront R&D costs, expensive prototyping, manufacturing considerations, and specialized facilities.
As one VC bluntly put it: "Robotics is inherently capital-intensive". "We've seen a tougher fundraising environment, deals taking longer, valuations being pressured." Because robots consume significant capital before showing returns, many VCs approach the sector with caution.
Robotics companies typically have longer development cycles. Getting from lab prototype to commercial product often takes years – testing the patience of investors who typically want returns within 5-7 years.
You've probably heard some version of "we love the tech, but come back when you've proven it at scale." The irony is you need funding to achieve that scale in the first place. This chicken-and-egg problem in robotics capital raising often forces startups to seek creative financing solutions.
Even with working technology, customers (especially enterprises or hospitals) can be slow to adopt new robotics solutions due to costs or integration complexity. In uncertain economic conditions, customers are "taking longer and pushing off expensive equipment purchases" – creating additional market risk on top of technological risk.
The pool of investors truly comfortable with robotics is relatively narrow. As F-Prime Capital highlighted, robotics investment accounts for roughly 10% of VC tech investments over the past five years (about $90B globally), indicating it's a substantial but niche slice. Competition for these specialized investors is intense.
Here's where things get interesting. Traditional VC is no longer the only option for robotics companies needing capital. Direct-to-investor fundraising for robotics startups – especially through regulation exemptions like Reg A+ and Reg CF – is opening new doors for hardware-intensive ventures.
This is where DealMaker's platform is transforming the funding landscape for robotics companies.
In simple terms:
Unlike traditional fundraising where only accredited investors can participate, these pathways allow ANYONE to invest in your robotics company. Both accredited and non-accredited individuals can become stakeholders in your venture.
For robotics companies in need of significant capital, Regulation A+ can be especially attractive. It sits between crowdfunding and a full IPO – sometimes dubbed a "mini-IPO." You file an offering circular with the SEC, but you're allowed to advertise the offering widely and raise money online from thousands of investors.
DealMaker's comprehensive platform streamlines this entire process, handling the complex compliance requirements while providing you with tools to engage potential investors effectively.
Monogram Orthopaedics represents one of the most compelling robotics fundraising success stories of recent years. This orthopedic surgical robotics company, developing advanced systems for knee and hip replacements along with 3D-printed personalized implants, faced a common challenge: traditional VCs weren't biting.
When venture capitalists said no to their breakthrough technology, Monogram made a strategic pivot that would ultimately transform the company. They turned to retail investors through Regulation A+ and Regulation CF offerings – a decision that would power their journey from startup to publicly traded company with DealMaker's help.
Monogram's fundraising journey is remarkable. After initial raises on other platforms, they partnered with DealMaker for their most critical capital formation efforts. Through DealMaker's platform, they raised nearly $16 million in a 2023 Reg A+ offering with over 5,000 investors, which set the stage for their successful Nasdaq listing.
The most impressive part? Even after going public – when most companies would rely solely on traditional capital markets – Monogram continued to leverage DealMaker's platform to engage their investor community. In a move that defied conventional wisdom, they raised an additional $13 million privately post-IPO through a unit offering to over 2,700 investors.
"When we started this journey, we needed capital that wouldn't come with the strings and dilution that traditional funding often requires," explains Monogram's leadership. "DealMaker's platform allowed us to control our destiny while building a community of supporters who believe in our vision."
In total, Monogram has raised over $70 million through various Regulation A+ and CF offerings, with DealMaker providing the technology and expertise for their most significant raises and their path to Nasdaq. This success story demonstrates how a hardware-intensive orthopedic robotics company can maintain control and ownership while accessing the capital needed to bring revolutionary technology to market.
Most importantly, their retail investor community has become a long-term strategic asset at every stage of growth – from startup through IPO and beyond.
Direct-to-investor fundraising offers something potentially more valuable than just capital: a community of supporters.
Mark Elenowitz, an expert who has helped companies navigate Reg A+, explains that "community-building and the momentum it generates" is the main reason companies choose to use Reg A+. "It's a great way to convert customers into shareholders and shareholders into customers."
For robotics startups, this approach can be particularly powerful. Your beta testers, enthusiastic fans, or excited industry professionals become owners with a vested interest in your success.
DealMaker's platform is specifically designed to facilitate this community-building aspect, turning your fundraising campaign into a powerful marketing and engagement tool.
Unlike traditional IPOs with restrictive "quiet periods," Reg A+ allows you to actively promote your offering. As Elenowitz notes: "Reg A allows you to market and use general solicitation" - "now they can go to Instagram and see a 30-second ad about an investment opportunity."
For robotics companies with compelling visual demos, this is a major advantage. DealMaker's platform enables you to showcase your robots in action to potential investors worldwide, creating engagement that traditional fundraising methods can't match.
Several robotics companies have successfully used DealMaker's platform for direct-to-investor fundraising:
Knightscope, which builds autonomous security robots (think R2-D2 meets mall cop), was an early adopter of Reg A+. Over several years, Knightscope raised over $70 million from more than 28,000 investors via successive Reg A+ offerings.
In January 2022, it took the final step of a Reg A+ "IPO", raising $22.3 million by selling shares at $10 each and listing on NASDAQ (ticker: KSCP).
The founder, William Santana Li, often credits their investor community for enabling the company's journey when traditional funding was scarce for a hardware startup in the security space. DealMaker's platform helped Knightscope maintain control (no single VC calling the shots) while creating thousands of brand ambassadors for their product.
Miso Robotics, famous for its burger-flipping robot "Flippy," took a non-traditional funding route from the start. Through DealMaker's platform, Miso raised more than $50 million from over 15,000 investors – one of the most successful equity crowdfunding campaigns in history.
By early 2022, the company's valuation hit $500M, and they continued to attract strategic partners (like fast-food chains and appliance makers) as investors. Miso's CEO Mike Bell noted that the interest from individual investors and restaurant industry players was a testament to the real market need they're addressing.
Miso demonstrated that compelling storytelling about a robot solving real-world problems (kitchen labor shortages) could translate into significant investment through DealMaker's platform. They've deployed Flippy in live restaurants like Dodgers Stadium and White Castle kitchens, providing tangible evidence of market traction.
Miso also shows that crowdfunding and institutional funding aren't mutually exclusive: alongside the crowd, they attracted strategic stakeholders like Levy Restaurants and CaliBurger, blending community money with corporate strategic money.
Whether you're pursuing venture capital, direct-to-investor funding through DealMaker, or a hybrid approach, certain strategies can dramatically improve your chances:
Even if you're primarily targeting VCs, demonstrating grassroots support can be a powerful signal. It shows market demand and creates FOMO (fear of missing out) – nobody wants to be the firm that passed on the robotics startup with a devoted following.
To position your robotics venture optimally in 2025's funding environment:
If your technology leverages cutting-edge AI to make your robots smarter, make this central to your pitch. Investors are fascinated by the infusion of AI into robotics. Startups building humanoid robots or advanced robotic "brains" are securing massive funding because they promise leaps in capability.
Even if your robot isn't a humanoid, any aspect of improved autonomy or adaptability thanks to AI will resonate with investors on DealMaker's platform.
Healthcare robotics is currently attracting significant attention due to its large market size and pressing needs. If you're developing a robotic-assisted surgery system or orthopedic platform, emphasize how you're positioned in this growing sector.
Other attractive markets include logistics, manufacturing, agriculture, and defense – especially if you can connect to themes like labor shortages or supply chain resilience.
Many robotics companies are adopting subscription or Robotics-as-a-Service (RaaS) models to lower adoption barriers. As one VC noted, companies are offering OPEX-based models (like price-per-pick for warehouse robots) so that clients can pay smaller amounts over time instead of a big CapEx purchase.
If your business includes recurring revenue streams rather than just one-time sales, highlight this aspect on your DealMaker campaign. It demonstrates you understand market challenges and have a sustainable growth plan.
If you're building in healthcare robotics (including orthopedic systems or surgical platforms), you're in a particularly promising position for fundraising through DealMaker.
Investors are excited about the potential for improved patient outcomes, large hospital budgets, and precedent for significant exits. However, they also recognize the challenges – regulatory approvals, longer timelines, and clinical validation requirements.
When raising capital through DealMaker's platform, highlight how you're addressing these specific risks. Monogram Orthopaedics effectively used this approach, attracting investors from outside traditional VC circles who believed in their vision for improved orthopedic surgery.
Healthcare robotics startups should also consider combining non-dilutive funding sources (like SBIR/NIH grants) with their DealMaker raises. Virtuoso Surgical, for example, secured NIH grants alongside their Reg A+ offering.
The robotics funding landscape in 2025 requires adaptability and creativity. While challenges exist, so do tremendous opportunities – particularly when you expand beyond traditional capital sources.
DealMaker's direct-to-investor platform has opened new avenues for robotics companies to raise capital while building engaged communities. Companies like Monogram Orthopaedics, Knightscope, and Miso Robotics have proven that connecting with thousands of individual investors can fuel significant growth and even lead to public listings.
This doesn't mean abandoning traditional investors. Many successful robotics startups now employ a hybrid approach – using DealMaker's platform to validate their concept with a community raise, then leveraging that momentum to attract strategic investors who bring industry connections.
Ultimately, fundraising success comes down to building confidence. Whether you're pitching to VCs or launching a campaign on DealMaker, demonstrate that your team understands the market, can deliver the technology, and has a clear vision for growth.
Be honest about the challenges – robotics is indeed difficult – but show that you have practical solutions for managing costs, timelines, and market adoption.
For robotics founders feeling stuck between ambitious visions and funding realities, remember that the path forward may be different than you initially imagined. With DealMaker's platform opening access to thousands of potential investors, you now have tools to take your case directly to people who believe in your vision.
The future of robotics venture funding is evolving – and by adapting your approach with DealMaker, you can position your company to thrive in this new landscape.